Background {#Sec1}
==========

Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is a rare, chronic disease caused by *SERPING1* gene mutations \[[@CR1]\]. Clinical manifestations include recurrent, unpredictable episodes of bradykinin-mediated swelling in subcutaneous or submucosal tissues that are associated with a heavy burden of illness \[[@CR2], [@CR3]\]. Attacks can range from mild to severe and debilitating \[[@CR4]\], negatively affecting patients' ability to attend school, be productive at work, or participate in daily social activities \[[@CR5]\].

Onset of symptoms typically begins within the first two decades of life (often by age 10--11 years), with intensity of attacks worsening during puberty \[[@CR6]\]. However, C1-INH-HAE attacks may occur at any age and recur throughout a patient's lifetime \[[@CR7], [@CR8]\]. As such, treatment of acute attacks is a lifelong necessity and can pose unique challenges for elderly patients. Presence of age-related pharmacokinetic and pharmacodynamic changes, coupled with the high likelihood of comorbid conditions for which multiple medications are required, underscores the importance of monitoring the safe use of medication in this population \[[@CR9]\]. To date, publications focused on managing C1-INH-HAE attacks in elderly patients are scarce. One observational registry study of 27 patients receiving an intravenously administered, plasma-derived C1-INH concentrate for the management of acute attacks demonstrated safe use in patients aged ≥ 65 years \[[@CR10]\].

Icatibant, a subcutaneously administered antagonist of the bradykinin B~2~ receptor, has demonstrated efficacy and safety for the treatment of acute attacks in adults with HAE type I/II in three Phase 3 randomized, double-blind studies \[[@CR11], [@CR12]\]. However, mean patient age was \< 65 years in all three trials \[[@CR11], [@CR12]\]. Although systemic exposure of icatibant has been shown to be increased in elderly patients, no effects on safety have been identified in this population \[[@CR13]\].

The Icatibant Outcome Survey (IOS) is an ongoing international, prospective, observational drug registry study (NCT01034969) designed to monitor real-world safety and effectiveness of icatibant. Patients who are currently receiving, or are candidates for, treatment with icatibant are eligible to participate. Here, we compare patient characteristics and safety-related findings in elderly versus younger patients with C1-INH-HAE type I/II enrolled in the IOS.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Data for this analysis were collected from July 2009 through February 28, 2018, across 59 sites in 13 countries. The IOS study is conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. Approvals were received from local ethics committees and/or health authorities, and patients provided written informed consent to participate.

Study design is presented in detail elsewhere \[[@CR14]\]. Briefly, patient data were recorded via electronic forms by physicians at baseline and during follow-up visits (occurring approximately every 6 months), including frequency and severity of icatibant-treated attacks since the previous visit, safety/tolerability issues with icatibant treatment, presence of comorbid conditions and use of concomitant medications.

Adverse event-related outcome measures {#Sec4}
--------------------------------------

Adverse events (AEs) were assessed by frequency of occurrence, relationship to icatibant (possibly/probably/not related), and seriousness and severity (mild/moderate/severe). AEs classified as "possibly related to treatment" were those that occurred within a reasonable time sequence following administration of icatibant and are biologically plausible. Alternatively, the AE could be explained by concurrent disease or other drugs/chemicals. AEs classified as "probably related to treatment" were those that occurred within a reasonable time sequence following administration of icatibant, are biologically plausible, and are unlikely to occur as a result of concurrent disease or other drugs/chemicals.

AEs were categorized in accordance with the Medical Dictionary for Regulatory Activities system organ class and preferred term, and analyzed by the proportions of occurrence (percentage of patients reporting an event). For reporting seriousness/relationship of AEs to icatibant, each patient was counted only once, and only the highest seriousness/relationship category was reported for that patient.

Statistical analysis {#Sec5}
--------------------

Descriptive analyses were conducted in younger patients (defined as ages \< 65 years) versus elderly patients (≥ 65 years). Age at the time of data extract was used to define the age subgroups. For patients who discontinued early or died, age at discontinuation or death was used. Differences between age groups were evaluated using the Wilcoxon test for baseline characteristics; the Fisher test for possibly/probably related AEs and individual comparisons of mild, moderate, and severe AEs; and the Chi square test for individual comparisons of serious and non-serious AEs. Due to the observational nature of the registry, all analyses were considered exploratory; P-values were interpreted descriptively.

Results {#Sec6}
=======

Baseline demographics and disease characteristics {#Sec7}
-------------------------------------------------

As of February 28, 2018, 872 patients with C1-INH-HAE type I/II were enrolled in the IOS (Table [1](#Tab1){ref-type="table"}). Significant differences between elderly versus younger patients, respectively, were noted for age at symptom onset (median 17.0 vs 12.0 years, P = 0.0001), age at diagnosis (median 41.0 vs 19.4 years, P \< 0.0001), and delay between symptom onset and diagnosis (median 23.9 vs 4.8 years, P \< 0.0001 \[Table [1](#Tab1){ref-type="table"}\]). When evaluated in relation to family history, median age at diagnosis was significantly higher in elderly than in younger patients, regardless of presence or absence of a family history (P \< 0.0001, Fig. [1](#Fig1){ref-type="fig"}a). Whereas delay in diagnosis was significantly higher in elderly versus younger patients with a family history (23.9 vs 3.5 years, respectively, P \< 0.0001); the difference between age groups was not significant in the absence of a family history (10.2 vs 9.1 years, P = 0.2954; Fig. [1](#Fig1){ref-type="fig"}b).Table 1Baseline characteristicsCharacteristicsElderly (≥ 65 years)Younger (\< 65 years)OverallP-value (elderly vs younger)Patients, n (%)100 (11.5)772 (88.5)872 (100) Type I89 (89.0)717 (92.9)806 (92.4) Type II11 (11.0)55 (7.1)66 (7.6)0.1680Sex Female, n (%)51 (51.0)471 (61.0)522 (59.9)0.0547Age at enrollment (years) Median (Q1, Q3)67.9 (63.8, 70.9)36.8 (27.0, 47.3)39.5 (27.9, 51.8)\< 0.0001Age at symptom onset (years) Median (Q1, Q3)17.0 (7.0, 25.0)12.0 (5.0, 18.0)12.0 (5.0, 19.0)0.0001Age at diagnosis (years) Median (Q1, Q3)41.0 (30.8, 59.0)19.4 (11.4, 30.2)21.1 (13.1, 33.8)\< 0.0001Delay in diagnosis, (years) Median (Q1, Q3)23.9 (5.9, 37.2)4.8 (0.21, 15.7)6.1 (0.3, 17.5)\< 0.0001Family history of C1-INH-HAE, n, % Yes71 (71.0)565 (73.2)636 (72.9) No11 (11.0)100 (13.0)111 (12.7) Unknown7 (7.0)50 (6.5)57 (6.5) Missing11 (11.0)57 (7.4)68 (7.8)0.6051Attack severity, n (%) Number of attacks^a^58153785959 Very mild11 (1.9)18 (0.3)29 (0.5) Mild51 (8.8)546 (10.2)597 (10.0) Moderate227 (39.1)2202 (40.9)2429 (40.8) Severe219 (37.7)1941 (36.1)2160 (36.2) Very severe73 (12.6)671 (12.5)744 (12.5)  Very mild, mild, moderate vs severe/very severe0.4393Attack location, n (%) Number of attacks^a^72660166742 Skin323 (44.5)2702 (44.9)3025 (44.9)0.958 Abdomen369 (50.8)3510 (58.3)3879 (57.5)0.438 Larynx38 (5.2)293 (4.9)331 (4.9) Other70 (9.6)216 (3.6)286 (4.2)Use of long-term prophylaxis, n (%)2 (3.2)8 (2.0)--0.6329Number of cardiovascular medications, per patient Number of patients4966115 Median (Q1, Q3)2.0 (1.0, 3.0)1.0 (1.0, 2.0)1.0 (1.0, 2.0)0.0019*C1-INH-HAE* hereditary angioedema with C1 inhibitor deficiency, *Q* quartile^a^Attacks with severity/location data included; attacks with "missing" or "unknown" severity/location excluded Fig. 1**a** Age at diagnosis in elderly and younger patients, with and without a family history and **b** delay in diagnosis in elderly and younger patients, with and without a family history^a^. The horizontal line inside each box indicates the median, the lower and upper borders of each box indicate the first and third quartiles, and the lowest and highest horizontal lines outside the box indicate the minimum and maximum value. ^a^A total of 113 patients with a family history had a negative delay in diagnosis (wherein diagnosis occurred before onset of symptoms, based on confirmatory laboratory testing); younger, n = 108; elderly, n = 5. Likewise, a total of five patients with no family history had a negative delay in diagnosis, all in the younger group

Of attacks with available severity data, there was no difference between groups (P = 0.4393) when comparing very mild/mild/moderate attacks versus severe/very severe attacks (Table [1](#Tab1){ref-type="table"}). Attacks at a single site versus multiple sites comprised the majority of attacks in both the elderly and younger groups (elderly, 653/726 attacks \[89.9%\]; younger, 5339/6016 attacks \[88.7%\]) and there was no significant difference in attack location (Table [1](#Tab1){ref-type="table"}).

Comorbid conditions and their treatment {#Sec8}
---------------------------------------

Elderly patients were significantly more likely than younger patients to have multiple comorbidities, both at baseline (IOS entry; 52.0% vs 11.1%, P \< 0.0001) and during the follow-up period (26.0% vs 11.5%, P = 0.0002). For example, elderly patients were significantly more likely to have hypertension, ischemic heart disease, heart failure, stroke/transient ischemic attack, bleeding disorders, gastrointestinal disorders, diabetes, pulmonary disease, or renal-urogenital disorders at baseline, and hypertension, bleeding disorders, diabetes, and hepatic disorders during the follow-up period (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). Similarly, elderly patients received a greater number of concomitant medications for cardiovascular/cerebrovascular conditions, both at baseline (median 2.0 vs 1.0 medications per patient, P = 0.0019; Table [1](#Tab1){ref-type="table"}) and during the follow-up period (median 2.0 vs 1.0 medications per patient, P = 0.1238).Table 2Select comorbid conditions at baseline and follow-upComorbid conditions, n (%)BaselineFollow-upElderly (≥ 65 years)Younger (\< 65 years)PElderly (≥ 65 years)Younger (\< 65 years)PBleeding4 (4.0)5 (0.6)0.01304 (4.0)5 (0.6)0.0130Cardiovascular/cerebrovascular50 (50)69 (8.9) \< 0.000126 (26.0)49 (6.3)\<0.0001Diabetes11 (11.0)17 (2.2)0.00016 (6.0)8 (1.0)0.0027Gastrointestinal11 (11.0)19 (2.5)0.00027 (7.0)24 (3.1)0.0757Hepatic1 (1.0)0 (0.0)0.11472 (2.0)1 (0.1)0.0362Immunological2 (2.0)25 (3.2)0.75922 (2.0)36 (4.7)0.3008Infections1 (1.0)8 (1.0)1.00004 (4.0)25 (3.2)0.5650Neoplasia3 (3.0)6 (0.08)0.07350 (0.0)2 (0.3)1.0000Neurological1 (1.0)9 (1.2)1.00003 (3.0)9 (1.2)0.1498Osteoarticular1 (1.0)7 (0.9)1.00002 (2.0)17 (2.2)1.0000Psychiatric7 (7.0)23 (3.0)0.07066 (6.0)25 (3.2)0.1549Pulmonary7 (7.0)11 (1.4)0.00232 (2.0)10 (1.3)0.6380Renal/urogenital4 (4.0)5 (0.6)0.01303 (3.0)6 (0.8)0.0735 Table 3Cardiovascular comorbidities at baseline and follow-upComorbid conditions, n (%)BaselineFollow-upElderly (≥ 65 years)Younger (\< 65 years)PElderly (≥ 65 years)Younger (\< 65 years)PHypertension48 (51.6)64 (9.0)\< 0.000113 (18.1)27 (5.3) 0.0004Angina2 (2.2)4 (0.6) 0.14350 (0.0)1 (0.2) 1.0000Ischemic heart disease5 (5.4)5 (0.7) 0.00280 (0.0)2 (0.4) 1.0000Heart failure2 (2.2)1 (0.1) 0.03631 (1.4)0 (0.0) 0.1248Stroke/transient ischemic attack6 (6.5)5 (0.7) 0.00061 (1.4)3 (0.6) 0.4147

AEs related to icatibant treatment {#Sec9}
----------------------------------

During the time covered by this analysis, icatibant was used to treat 6798 attacks in 574 patients, with 715 icatibant-treated attacks reported by 63 (63.0%) elderly patients. Elderly and younger patients were similarly likely to have at least one treated attack (63.0% vs 66.2%, P = 0.527).

A similar percentage of elderly and younger patients experienced at least one AE possibly or probably related to icatibant (2.0% vs 2.7%; Table [4](#Tab4){ref-type="table"}). No serious AEs (SAEs) occurring in elderly patients were judged to be possibly related to icatibant, whereas two younger patients reported three possibly related SAEs; one patient reporting gastritis (n = 1) and reflux esophagitis (n = 1), the other patient reporting angioedema crisis (n = 1).Table 4Overall summary of AEsElderly (≥ 65 years)Younger (\< 65 years)Patients (n = 100)EventsPatients (n = 772)EventsTotal AEs, n (%)28 (28.0)86 (100.0)164 (21.2)374 (100.0)Occurrence of ≥ 1 icatibant-related AE, n (%)2 (2.0)19 (22.1)21 (2.7)68 (18.2)AEs by relationship to icatibant use, n (%) Not recorded0 (0.0)0 (0.0)11 (1.4)28 (7.5) Not related26 (26.0)67 (77.9)132 (17.1)278 (74.3) Possibly related0 (0.0)0 (0.0)5 (0.6)34 (9.1) Probably related2 (2.0)19 (22.1)16 (2.1)34 (9.1)Icatibant-related AEs by seriousness, n (%) Serious0 (0.0)0 (0.0)2 (0.3)3 (4.4) Not serious2 (2.0)19 (100.0)19 (2.5)65 (95.6)*AE* adverse event

The occurrence of mild and moderate AEs was similar between elderly and younger patients (P = 0.2170 and P = 0.2666, respectively). During the study, there were no deaths linked to treatment with icatibant.

A total of eight younger patients experiencing AEs had an older family member with C1-INH-HAE, however only two of these younger patients had an older family member (their father) who also experienced AEs. No patterns were found in the type of AEs experienced by related patients.

Icatibant-related AEs by system organ class {#Sec10}
-------------------------------------------

Excluding off-label use and pregnancy-related AEs (evaluated for regulatory purposes), all related events in elderly patients were attributed to general disorders/administration site conditions, whereas treatment-related events in younger patients occurred across various system organ classes, including general disorders/administration site conditions, vascular disorders, skin/subcutaneous tissue disorders, gastrointestinal disorders, nervous system disorders, and others (Table [5](#Tab5){ref-type="table"}).Table 5AEs possibly/probably related to icatibant, by system organ class and preferred term^a^PatientsElderly (≥ 65 years) (n = 100)Younger (\< 65 years) (n = 772)Overall (n = 872)Any AE n (%)2 (2.0)21 (2.7)23 (2.6)General disorders and administration site conditions2 (2.0)15 (1.9)17 (1.9) Injection site erythema1 (1.0)9 (1.2)10 (1.1) Pain0 (0.0)3 (0.4)3 (0.3) Application site erythema0 (0.0)2 (0.3)2 (0.2) Application site pain0 (0.0)2 (0.3)2 (0.2) Infusion site pain1 (1.0)1 (0.1)2 (0.2) Drug ineffective0 (0.0)1 (0.1)1 (0.1) Infusion site erythema1 (1.0)0 (0.0)1 (0.1) Injection site pain1 (1.0)0 (0.0)1 (0.1) Injection site hemorrhage0 (0.0)1 (0.1)1 (0.1) Localized edema0 (0.0)1 (0.1)1 (0.1) Non-cardiac chest pain0 (0.0)1 (0.1)1 (0.1) Edema0 (0.0)1 (0.1)1 (0.1) Therapeutic product ineffective0 (0.0)1 (0.1)1 (0.1) Infusion site urticaria1 (1.0)0 (0.0)1 (0.1) Administration site reaction1 (1.0)0 (0.0)1 (0.1) Asthenia0 (0.0)1 (0.1)1 (0.1)Vascular disorders0 (0.0)3 (0.4)3 (0.3) Hyperemia0 (0.0)2 (0.3)2 (0.2) Hot flush0 (0.0)1 (0.1)1 (0.1)Skin and subcutaneous tissue disorders0 (0.0)3 (0.4)3 (0.3) Skin reaction0 (0.0)2 (0.3)2 (0.2) Angioedema0 (0.0)1 (0.1)1 (0.1)Gastrointestinal disorders0 (0.0)4 (0.5)4 (0.5) Nausea0 (0.0)2 (0.3)2 (0.2) Abdominal distension0 (0.0)1 (0.1)1 (0.1) Abdominal pain upper0 (0.0)1 (0.1)1 (0.1) Reflux esophagitis0 (0.0)1 (0.1)1 (0.1) Hiatus hernia0 (0.0)1 (0.1)1 (0.1) Gastritis0 (0.0)1 (0.1)1 (0.1)Nervous system disorders0 (0.0)1 (0.1)1 (0.1) Post-herpetic neuralgia0 (0.0)1 (0.1)1 (0.1)Investigations0 (0.0)1 (0.1)1 (0.1) Blood pressure decreased0 (0.0)1 (0.1)1 (0.1)Infections and infestations0 (0.0)1 (0.1)1 (0.1) Herpes zoster0 (0.0)1 (0.1)1 (0.1)Psychiatric disorders0 (0.0)1 (0.1)1 (0.1) Depression0 (0.0)1 (0.1)1 (0.1)^a^Excludes AEs related to off-label use and pregnancy; *AE* adverse event

Discussion and conclusions {#Sec11}
==========================

To our knowledge, this is the first analysis that compares patient characteristics and safety and tolerability of icatibant in elderly versus younger patients with C1-INH-HAE. Findings from our analysis revealed a significantly older age at diagnosis in elderly versus younger patients with C1-INH-HAE, regardless of family history. Interestingly, delay in diagnosis was significantly longer in elderly versus younger patients in the presence of a positive family history, whereas the delay was similar for both age groups in the absence of a family history. This may have occurred due to the substantially larger number of younger patients with a positive family history (prompting earlier diagnosis), as well as better diagnostic work-up in families in current clinical practice. The delay in elderly patients with a family history may also be caused by the fact that their relatives from previous generations may have given up seeking medical advice for their condition and were living with symptoms, having lacked a formal diagnosis or effective C1-INH-HAE treatments in their own youth.

Our analysis did not reveal any new or unexpected safety concerns. Despite the fact that elderly patients had significantly more comorbidities and were receiving a greater number of concomitant medications, the occurrence of icatibant-related AEs was similar in the treated elderly versus younger population, with no significant differences noted between groups with regard to seriousness or severity of AEs. These findings correlate with those previously reported in an observational drug registry study by Bygum et al., who found no unexpected safety concerns in older versus younger patients treated with an intravenously administered, plasma-derived C1-INH in a real-world setting \[[@CR10]\]. Additionally, no trends were noted with regard to the type of AEs experienced by younger patients who were related to an older patient enrolled in the IOS.

Our study had several limitations, including an uncontrolled clinical environment inherent in an observational study design; description of AEs relied heavily on patient recall. Additionally, substantially fewer elderly than younger patients were enrolled.

Despite the limitations, our real-world analysis provides valuable insight with regard to clinical characteristics of elderly patients with C1-INH-HAE and the safety of treating acute attacks with icatibant in this patient population.
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